Recombinant Factor IX (BAX 326): A Phase 1/3, Prospective, Controlled, Multicenter Study Evaluating Pharmacokinetics, Efficacy, Safety and Immunogenicity in Previously Treated Patients With Severe or Moderately Severe Hemophilia B
Latest Information Update: 10 Jan 2022
At a glance
- Drugs Nonacog gamma (Primary)
- Indications Haemophilia B
- Focus Pharmacokinetics; Registrational
- Sponsors Baxalta; Baxter International
- 10 Jan 2022 New source identified and integrated (Japan Pharmaceutical Information Center - Clinical Trials Information record: JapicCTI101371).
- 19 Jun 2019 This trial has been completed in Spain, according to European Clinical Trials Database.
- 23 Jan 2014 New trial record